Rizvi N, et al. Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial. Abstract OA04.07. WCLC 2019, 7-10 september, Barcelona, Spanje.
Neoadjuvant letrozol plus taselisib bij ER+ HER2- stadium I-III borstkanker
okt 2019 | Borstkanker